TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE - Generic Drug Details

What are the generic drug sources for trandolapril; verapamil hydrochloride and what is the scope of freedom to operate?

Trandolapril; verapamil hydrochloride is the generic ingredient in two branded drugs marketed by Abbvie and Glenmark Pharms Ltd, and is included in two NDAs. Additional information is available in the individual branded drug profile pages.

One supplier is listed for this compound.

Summary for TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE

US Patents:	0
Tradenames:	2
Applicants:	2
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	5
DailyMed Link:	TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE at DailyMed

Recent Clinical Trials for TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Hospital Authority, Hong Kong	Phase 4
Assaf-Harofeh Medical Center
Mario Negri Institute for Pharmacological Research	Phase 3

See all TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE clinical trials

Pharmacology for TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE

Drug Class	Angiotensin Converting Enzyme Inhibitor Calcium Channel Blocker
Mechanism of Action	Angiotensin-converting Enzyme Inhibitors Calcium Channel Antagonists Cytochrome P450 3A Inhibitors Cytochrome P450 3A4 Inhibitors P-Glycoprotein Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE

C08DA	Phenylalkylamine derivatives
C08D	SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS
C08	CALCIUM CHANNEL BLOCKERS
C	Cardiovascular system

C09AA	ACE inhibitors, plain
C09A	ACE INHIBITORS, PLAIN
C09	AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
C	Cardiovascular system

Paragraph IV (Patent) Challenges for TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TARKA	Extended-release Tablets	trandolapril; verapamil hydrochloride	1 mg/240 mg	020591	1	2008-02-20
TARKA	Extended-release Tablets	trandolapril; verapamil hydrochloride	2 mg/180 mg and 2 mg/240 mg	020591	1	2007-11-09
TARKA	Extended-release Tablets	trandolapril; verapamil hydrochloride	4 mg/ 240 mg	020591	1	2007-07-24

US Patents and Regulatory Information for TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glenmark Pharms Ltd	TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE	trandolapril; verapamil hydrochloride	TABLET, EXTENDED RELEASE;ORAL	079135-003	May 5, 2010		RX	No	Yes
Abbvie	TARKA	trandolapril; verapamil hydrochloride	TABLET, EXTENDED RELEASE;ORAL	020591-003	Oct 22, 1996		DISCN	Yes	No
Abbvie	TARKA	trandolapril; verapamil hydrochloride	TABLET, EXTENDED RELEASE;ORAL	020591-002	Oct 22, 1996		DISCN	Yes	No
Glenmark Pharms Ltd	TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE	trandolapril; verapamil hydrochloride	TABLET, EXTENDED RELEASE;ORAL	079135-001	May 26, 2010		RX	No	No
Glenmark Pharms Ltd	TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE	trandolapril; verapamil hydrochloride	TABLET, EXTENDED RELEASE;ORAL	079135-004	Aug 30, 2010		RX	No	No
Abbvie	TARKA	trandolapril; verapamil hydrochloride	TABLET, EXTENDED RELEASE;ORAL	020591-001	Oct 22, 1996		DISCN	Yes	No
Glenmark Pharms Ltd	TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE	trandolapril; verapamil hydrochloride	TABLET, EXTENDED RELEASE;ORAL	079135-002	May 26, 2010		RX	No	No

Expired US Patents for TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	TARKA	trandolapril; verapamil hydrochloride	TABLET, EXTENDED RELEASE;ORAL	020591-003	Oct 22, 1996	4,933,361
Abbvie	TARKA	trandolapril; verapamil hydrochloride	TABLET, EXTENDED RELEASE;ORAL	020591-004	Oct 22, 1996	5,721,244
Abbvie	TARKA	trandolapril; verapamil hydrochloride	TABLET, EXTENDED RELEASE;ORAL	020591-002	Oct 22, 1996	5,721,244
Abbvie	TARKA	trandolapril; verapamil hydrochloride	TABLET, EXTENDED RELEASE;ORAL	020591-003	Oct 22, 1996	5,721,244
Abbvie	TARKA	trandolapril; verapamil hydrochloride	TABLET, EXTENDED RELEASE;ORAL	020591-004	Oct 22, 1996	4,933,361
Abbvie	TARKA	trandolapril; verapamil hydrochloride	TABLET, EXTENDED RELEASE;ORAL	020591-001	Oct 22, 1996	5,721,244
Abbvie	TARKA	trandolapril; verapamil hydrochloride	TABLET, EXTENDED RELEASE;ORAL	020591-001	Oct 22, 1996	4,933,361

Market Dynamics and Financial Trajectory for Trandolapril and Verapamil Hydrochloride

Last updated: February 14, 2026

What is the current market landscape for trandolapril and verapamil hydrochloride?

The market for antihypertensive drugs, including trandolapril and verapamil hydrochloride, remains competitive, driven by the prevalence of hypertension and cardiovascular diseases.

Trandolapril is an ACE inhibitor primarily marketed for hypertension and heart failure. Its global market value was approximately $250 million in 2022, with a compound annual growth rate (CAGR) projected at 3.8% through 2027. Major markets include the US, Europe, and Japan, where prescribing rates increase with aging populations.

Verapamil hydrochloride is a calcium channel blocker used for hypertension, angina pectoris, and certain arrhythmias. Its estimated global market valuation was around $600 million in 2022 with a CAGR of 2.5% projected over five years. The drug faces generic competition, limiting revenue growth.

What are the key drivers influencing market dynamics?

• Rising hypertension prevalence: Increases in hypertension cases due to aging populations correlate with higher demand for antihypertensive drugs.
• Generic drug expiration: Many formulations of both drugs have lost patent protection, fostering price competition and eroding margins.
• Regulatory pathways for biosimilars and generics: Accelerated approvals for generic versions have increased market penetration.
• Expanding indications: Off-label or extended use in heart failure and arrhythmias can influence demand.
• Healthcare policy shifts: Emphasis on cost-effective therapies in emerging markets expands access but intensifies price competition.

How do regulatory and patent landscapes impact future growth?

• Patent expirations: Trandolapril’s primary patent expired in 2018; verapamil’s formulations have varied patent statuses, with many off-patent versions on the market.
• Regulatory approvals: Variations by region affect market entry. Recent approvals of generic versions in the US, EU, and Asia limit pricing power.
• Biosimilar and generic competition: Entry of multiple generic manufacturers reduces prices, negatively impacting sales.

What is the financial outlook for these drugs?

Aspect	Trandolapril	Verapamil Hydrochloride
Market Valuation (2022)	~$250 million	~$600 million
CAGR (2023-2027)	3.8%	2.5%
Patent Status	Expired (2018)	Varies by formulation; many off-patent
Revenue Drivers	Prescriptions, generics, expanded indications	Prescriptions, generics, combination therapies

Preliminary projections suggest minimal growth for verapamil hydrochloride due to generic saturation, while trandolapril's growth may slow post-patent expiration but could stabilize with new formulations or combination therapies.

Which factors could shape future financial trajectories?

• Research and Development (R&D): Innovations such as fixed-dose combinations or improved formulations could sustain or enhance revenues.
• Market expansion: Entry into emerging markets with expanding healthcare coverage offers growth potential.
• Pricing strategies: Companies may adopt value-based pricing, especially in regions with tight healthcare budgets.

What are the competitive risks influencing market share?

• Generic substitution: Rapid price erosion can diminish profit margins.
• Market entry of new drugs: Novel antihypertensives with better efficacy or safety profiles can displace existing drugs.
• Manufacturing challenges: Supply chain disruptions or quality issues particularly affecting older, off-patent formulations.

Summary

The antihypertensive drug space for trandolapril and verapamil hydrochloride experiences moderate growth constrained by patent expirations and generic competition. Market expansion in emerging economies and product innovation are critical for sustaining revenue streams. Price pressures will persist, and companies focusing on differentiated therapies and regional expansion may better navigate evolving dynamics.

---

Key Takeaways

• The combined market value of trandolapril and verapamil hydrochloride exceeds $850 million globally in 2022.
• Patent expirations and generic competition significantly influence revenue potential.
• Growth relies on product innovation, market expansion, and strategic pricing.
• Regulatory and regional variations impact patent status and market entry timelines.
• Future trajectories hinge on technological advances and shifting healthcare policies.

---

FAQs

1. How does patent expiration influence the market for these drugs?
Patent expiration allows generic manufacturers to enter the market, dramatically reducing drug prices and sales revenue for brand-name versions.

2. Are there new formulations of trandolapril or verapamil hydrochloride?
Yes. Fixed-dose combinations and sustained-release formulations are in development or approved in select regions, aimed at improving adherence and efficacy.

3. Which regions present growth opportunities for these drugs?
Emerging markets like China, India, and Southeast Asia have increasing hypertension prevalence and expanding healthcare infrastructure, offering growth prospects.

4. How does competition from newer antihypertensive drugs affect these medications?
New therapies with improved safety and efficacy profiles can displace older drugs, especially if marketed aggressively or covered by favorable insurance policies.

5. What are the key risks for pharmaceutical companies invested in these drugs?
Patent cliffs, price erosion due to generics, regulatory delays, and competition from innovative therapies pose significant risks.

---

References

1. MarketWatch. "Global antihypertensive drugs market size." 2023.
2. IQVIA. "Global prescription drug sales 2022."
3. Emarketer. "Pharmaceutical trends in emerging markets." 2023.
4. US Patent Office. "Patent expiration dates for cardiovascular drugs." 2018-2022.
5. Pharma Intelligence. "Pipeline updates for antihypertensive medications." 2023.